Pound foolish and penny wise-when will dosing of rifampicin be optimised?
Name:
Publisher version
View Source
Access full-text PDFOpen Access
View Source
Check access options
Check access options
Average rating
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Star rating
Your vote was cast
Thank you for your feedback
Thank you for your feedback
Authors
Magis-Escurra, CecileAnthony, Richard M
van der Zanden, Adri G M
van Soolingen, Dick
Alffenaar, Jan-Willem C
Type
ArticleLanguage
en
Metadata
Show full item recordTitle
Pound foolish and penny wise-when will dosing of rifampicin be optimised?Published in
Lancet Respir Med 2018; 6(4):e11-e12PMID
29396032ae974a485f413a2113503eed53cd6c53
10.1016/S2213-2600(18)30044-4
Scopus Count
Collections
Related articles
- Considering the role of four months of rifampin in the treatment of latent tuberculosis infection.
- Authors: Reichman LB, Lardizabal A, Hayden CH
- Issue date: 2004 Oct 15
- Is the recommendation not to use rifampin plus pyrazinamide for latent tuberculosis treatment always imperative?
- Authors: Cazzadori A, Allegranzi B, Scardigli A, Favari F, Concia E
- Issue date: 2004 Aug
- Evaluation of high- versus standard-dose rifampin in Indonesian patients with pulmonary tuberculosis.
- Authors: Ruslami R, Nijland H, Aarnoutse R, Alisjahbana B, Soeroto AY, Ewalds S, van Crevel R
- Issue date: 2006 Feb
- Review of the Indian market of anti-tuberculosis drugs: focus on the utilisation of rifampicin-based products.
- Authors: Catalani E
- Issue date: 1999 Nov
- Completing tuberculosis prophylaxis in jail: targeting treatment and a comparison of rifampin/pyrazinamide with isoniazid regimens.
- Authors: Lambert LA, Ijaz K, Navin TR
- Issue date: 2005 Feb